CClinicalTrials.gg
TerminatedNCT03369509BdDAllergoUpdated Feb 6, 2019

Allergic Versus Non Allergic Hypersensitivity Drug Reaction (BdDAllergo)

An observational study in Allergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross Reaction, sponsored by University Hospital, Grenoble. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-06.

Sponsored by University Hospital, Grenoble · Observational

Why this study was terminated
departure of the investigator from the CHU Grenoble Alpes
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
456
Ages
18 Years and older
Sex
All
01

Study summary

The creation of a database containing the medical data of patients followed in allergology at the University Hospital of Grenoble will permit to study allergic versus non-allergic hypersensitivity drug reaction as well as the risk of cross-reactions between medicinal drugs belonging to the same pharmacological class.

The main objectives of the study are to estimate and to compare the proportion of allergic hypersensitivity drug reaction and the proportion of non allergic hypersensitivity drug reaction, and to characterize these two types of hypersensitivity drug reaction on clinical, biological and chronological aspects.

In a second time, ancillary study will be conducted in order to :

  • identify drugs that potentially induced histamine-liberation in patients diagnosed with non allergic hypersensitivity drug reaction
  • investigate the risk of cross-reactions between drugs belonging to the same pharmacotherapeutic class in patients diagnosed with allergic hypersensitivity drug reaction.
Read the detailed description

This study is an observational cohort study conducted at University Hospital of Grenoble. It include retrospectively and prospectively the patients followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction. The data are collected in a database from medical consultation reports that are systematically reported to the pharmacovigilance regional center. An anonymization number is assigned for each patient included in the study.The data collected include patient's personal and family medical history, a clinical, biological and chronological description of the hypersensitivity reaction, the results of the immunoallergologic skin tests as well as the final diagnosis.

02

Conditions studied

  • Allergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross Reaction

Keywords

  • Drug hypersensitivity, drug allergy, cross reaction
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients who realize a complete immunoallergologic tests investigations at the University Hospital of Grenoble.

Inclusion criteria

  • Cases where a non-iatrogenic cause was finally identified

Exclusion criteria

Exclusion Criteria:

  • For the estimation and comparison of the proportions, the patients who haven't carried out all their immunoallergologic tests investigations at the University Hospital of Grenoble are not included (this concerns patient who have realized only oral rechallenge test at hospital)
  • To realize the comparative analysis of allergic versus non-allergic hypersensitivity drug reaction : cases that are insufficiently documented on clinical, biological and / or chronological aspects are excluded. This concerns especially patients who realize immunoallergologic tests investigations after a skin reaction that occurred "in childhood".
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
456 participants (actual)
Patient registry
No

Groups and cohorts

  • hypersensitivity drug reaction

    Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.

05

What researchers measure

Primary outcomes

  1. Allergic Versus Non Allergic Hypersensitivity Drug Reaction

    Conclusion of the immunoallergologic tests investigations : * allergic hypersensitivity drug reaction case are diagnosed when the skin tests are positive or the skin tests are negative but the oral rechallenge test is positive. * non allergic hypersensitivity drug reaction case are diagnosed when the skin tests are negative AND the oral rechallenge test is negative.

    Time frame: Through study completion, an average of 5 years

Secondary outcomes

  1. - To determine the proportion of drugs involved in in allergic hypersensitivity drug reaction for each pharmacotherapeutic class

    Immunoallergologic tests investigations that conclude to an allergic hypersensitivity drug reaction

    Time frame: Through study completion, an average of 5 years

  2. immediate allergic hypersensitivity and delayed allergic hypersensitivity on clinical, biological and chronological aspects

    Conclusion of the immunoallergologic tests investigations : * immediate allergic hypersensitivity drug reaction case are diagnosed when the skin tests are positive at 20 minutes for Prick tests or IDR or the skin tests are negative but the oral rechallenge test is positive immediately. * delayed allergic hypersensitivity drug reaction case are diagnosed when the skin tests are positive at 24 or 48 hours for IDR or the skin tests are negative but the oral rechallenge test is positive in the days following the reintroduction of treatment.

    Time frame: Through study completion, an average of 5 years

  3. To determine the proportion of drugs that potentially induced histamine-liberation in patients diagnosed with non allergic hypersensitivity drug reaction for each pharmacotherapeutic class

    Conclusion of the immunoallergologic tests investigations : - non allergic hypersensitivity drug reaction case are diagnosed when the skin tests are negative AND the oral rechallenge test is negative.

    Time frame: Through study completion, an average of 5 years

  4. - Proportion of cross-reaction between drugs belonging to the same pharmacotherapeutic class in patients diagnosed with allergic hypersensitivity drug reaction.

    Conclusion of the immunoallergologic tests investigations : - Cross-reaction are diagnosed when the immunoallergologic test investigation is positive for medicinal products belonging to the same pharmacotherapeutic class as the responsible treatment of the skin reaction.

    Time frame: ancillary study, Through study completion, an average of 5 years

06

Study locations

1 site
  • UniversityHospitalGrenoble
    Grenoble, 38043, France
07

References and documents

Publications

  • Cousin F, Catelain A, Philips K, Favier B, Queuille E, Nicolas JF. [Immediate hypersensitivity is rarely implicated in drug induced urticaria]. Ann Dermatol Venereol. 2003 Mar;130(3):321-4. French. PubMed 12746667 ↗
  • Ponvert C, Scheinmann P. [Allergic and pseudo-allergic reactions to betalactam antibiotics]. Arch Pediatr. 2003 Jul;10(7):658-65. doi: 10.1016/s0929-693x(03)00272-0. No abstract available. French. PubMed 12907084 ↗
  • Nosbaum A, Pralong P, Rozieres A, Dargaud Y, Nicolas JF, Berard F. [Delayed-type hypersensitivity to heparin: diagnosis and therapeutic management]. Ann Dermatol Venereol. 2012 May;139(5):363-8. doi: 10.1016/j.annder.2012.01.017. Epub 2012 Mar 9. French. PubMed 22578340 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03369509
Lead sponsor
University Hospital, Grenoble
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
May 29, 2017
Primary completion
Aug 1, 2018
Completion
Aug 1, 2018
Last update
Feb 6, 2019

Study contacts

Nassima YAHIAOUI
principal investigator · UniversityHospital Grenoble

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion